SCHEDULE 13G: Adage Capital Management Discloses 9.86% Stake in Monopar Therapeutics

Adage Capital Management, L.P., along with its managing members Robert Atchinson and Phillip Gross, has disclosed a significant beneficial ownership of 9.86% in Monopar Therapeutics' common stock as of December 31, 2024.

Summary

• Adage Capital Management, L.P., a Delaware limited partnership, along with Robert Atchinson and Phillip Gross, has filed a Schedule 13G indicating beneficial ownership in Monopar Therapeutics.
• The reporting persons collectively beneficially own 599,195 shares of Monopar Therapeutics' Common Stock.
• This ownership represents 9.86% of the total outstanding Common Stock of Monopar Therapeutics.
• The percentage is calculated based on an aggregate of 6,076,451 shares of Common Stock outstanding, which includes 5,277,796 shares outstanding as of December 17, 2024, and an additional 798,655 shares issued as reported in the Issuer's Prospectus Supplement filed on December 23, 2024.
• The shares are held with shared voting power and shared dispositive power by the reporting persons.
• The acquisition of these securities was made in the ordinary course of business and not for the purpose of changing or influencing the control of Monopar Therapeutics.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain language that suggests a positive or negative sentiment regarding the company's performance or outlook.

Risks

• The filing explicitly states that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose or with the effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance from Monopar Therapeutics or the reporting persons regarding the company's future performance or strategic direction.

Industry Context

This filing indicates a significant institutional investment by Adage Capital Management in Monopar Therapeutics, a company operating in the biotechnology or pharmaceutical sector. Such disclosures are common as institutional investors cross ownership thresholds, providing transparency into major shareholder positions.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Adage Capital Management may influence market perception and investor confidence in Monopar Therapeutics.

Key Dates

Keywords

Monopar Therapeutics, Adage Capital Management, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investment, Equity Stake, SEC Filing